Your session is about to expire
← Back to Search
INC280 for Glioblastoma
Study Summary
This trial is testing a new combination of drugs to treat people with GBM who have progressed after other treatments or who can't have surgery.
- Glioblastoma
- Gliosarcoma
- Colorectal Cancer
- Kidney Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 20 Patients • NCT02019693Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there any openings for participants in this clinical trial currently?
"This research has already ceased recruitment, as the first posting was published on September 22nd 2015 with a final update made to it on November 1st 2022. However, if you are seeking active clinical studies that involve gliosarcoma or INC280 there are currently 1388 and 369 trials respectively recruiting patients."
Could you please elaborate on other scientific endeavors that have involved INC280?
"In 2004, the first trial of INC280 was conducted at Memoral Sloan Kettering Basking Ridge (Follow Up Only). Subsequently, 1020 studies have been completed. Currently, 369 research initiatives are underway; with a significant portion being in Kansas City, Missouri."
How many healthcare centers are carrying out this clinical experiment?
"Patients can be enrolled in this research project at HCA Midwest - Kansas City, Sarah Cannon Research Institute at HealthONE and Yale School of Medicine as well as 5 additional medical facilities."
Can you explain what conditions INC280 is typically administered to treat?
"INC280 is frequently prescribed for the treatment of malignant neoplasms. Moreover, it also has therapeutic potential in recurrent platinum sensitive primary peritoneal cancer, stage iv epithelial ovarian cancer that was initially surgically removed, and locally advanced nonsquamous non-small cell lung cancer."
How many participants are a part of this research project?
"Unfortunately, this experiment is not presently looking for volunteers. This clinical trial was first published on September 22nd 2015 and last modified on November 1st 2022. If you are interested in alternative studies, there are 1388 trials enrolling patients with gliosarcoma and 369 research projects recruiting participants for INC280 treatments."
What potential risks are associated with INC280 when used therapeutically?
"Due to the early stage of this trial, there is limited data regarding INC280's efficacy and safety. Hence, we have rated it a 1 on our scale from one to three."
Share this study with friends
Copy Link
Messenger